SML0057

Camostat mesylate

≥98% (HPLC), Serine protease inhibitor, powder

• Sinónimos: 4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]benzeneacetic acid 2-(dimethylamino)-2-oxoethyl ester methanesulfonate; FOY 305; FOY-S 980; Foipan mesylate
• Fórmula empírica (notación de Hill): C₂₀H₂₂N₄O₅·CH₃SO₃H
• Número CAS: 59721-29-8
• Peso molecular: 494.52
• UNSPSC Code: 12352203
• PubChem Substance ID: 329825123
• NACRES: NA.77
• MDL number: MFCD00941410
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Nombre del producto: Camostat mesylate, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to tan
• solubility: H₂O: ≥24 mg/mL
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: CS(O)(=O)=O.CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1
• InChI: 1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
• InChI key: FSEKIHNIDBATFG-UHFFFAOYSA-N

Descripción

Application

Camostat mesylate may be used in cell signaling studies.

Camostat mesylate has been used to determine the effect of transmembrane protease, serine (TMPRSS) family proteases on cell-cell fusion.

Biochem/physiol Actions

Camostat is a serine protease inhibitor, airway epithelial sodium channel (ENaC) attenuator.

Camostat is a synthetic, orally bioavailble serine protease inhibitor and airway epithelial sodium channel (ENaC) attenuator.

Camostat mesylate (CM) is used to treat pancreatitis and reflux esophagitis after gastrectomy.

Camostat mesylate inhibits the production of TNF-α and monocyte chemoattractant protein-1 (MCP-1) by monocytes. It also inhibits the activity of pancreatic stellate cells. Camostat mesylate regulates the cytokine expression and inflammation and is effective in the treatment of dibutyltin dichloride-induced rat pancreatic fibrosis.

Features and Benefits

This compound is featured on the Acid-Sensing (Proton-gated) Ion Channels (ASICs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07,GHS09
• signalword: Warning
• hcodes: H315,H319,H335,H400
• pcodes: P261 - P264 - P271 - P273 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Aquatic Acute 1 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable